BR112015021524A2 - derivados de sulfonil quinolina e usos dos mesmos - Google Patents

derivados de sulfonil quinolina e usos dos mesmos

Info

Publication number
BR112015021524A2
BR112015021524A2 BR112015021524A BR112015021524A BR112015021524A2 BR 112015021524 A2 BR112015021524 A2 BR 112015021524A2 BR 112015021524 A BR112015021524 A BR 112015021524A BR 112015021524 A BR112015021524 A BR 112015021524A BR 112015021524 A2 BR112015021524 A2 BR 112015021524A2
Authority
BR
Brazil
Prior art keywords
quinoline derivatives
sulfonyl quinoline
sulfonyl
compounds
compositions
Prior art date
Application number
BR112015021524A
Other languages
English (en)
Inventor
Lee Hoyun
Pundir Sheetal
Raja Solomon Viswas
Original Assignee
Advanced Medical Res Institute Of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medical Res Institute Of Canada filed Critical Advanced Medical Res Institute Of Canada
Publication of BR112015021524A2 publication Critical patent/BR112015021524A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

resumo “derivados de sulfonil quinolina e usos dos mesmos” a presente revelação descreve compostos de sulfonil quinolina, composições compreendendo estes compostos e seus usos, em particular para o tratamento de câncer. particularmente, a presente revelação inclui compostos de fórmula (i) e composições e seus usos.
BR112015021524A 2013-03-04 2014-02-18 derivados de sulfonil quinolina e usos dos mesmos BR112015021524A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361772032P 2013-03-04 2013-03-04
PCT/CA2014/000121 WO2014134705A1 (en) 2013-03-04 2014-02-18 Quinoline sulfonyl derivatives and uses thereof

Publications (1)

Publication Number Publication Date
BR112015021524A2 true BR112015021524A2 (pt) 2017-07-18

Family

ID=51490511

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021524A BR112015021524A2 (pt) 2013-03-04 2014-02-18 derivados de sulfonil quinolina e usos dos mesmos

Country Status (8)

Country Link
US (1) US9975852B2 (pt)
EP (1) EP2964625B1 (pt)
JP (1) JP6509747B2 (pt)
KR (1) KR20150123908A (pt)
CN (1) CN105308031B (pt)
BR (1) BR112015021524A2 (pt)
CA (1) CA2903082C (pt)
WO (1) WO2014134705A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
EP2958895B1 (en) 2013-02-20 2020-08-19 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
CA3020090A1 (en) 2015-04-24 2016-10-27 University Of Louisville Research Foundation, Inc. Selective pfkfb4 inhibitors for the treatment of cancer
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3073952A1 (en) 2017-08-31 2019-03-07 University Of Louisville Research Foundation, Inc. Quinoline derivative, compositions comprising this compound and uses thereof in the treatment of cancer
US10774046B2 (en) 2017-10-26 2020-09-15 University Of Louisville Research Foundation, Inc. Inhibitors for the treatment of cancer and related methods
CN108451939B (zh) * 2018-05-14 2021-11-16 兰州大学 2,4-二硝基苯磺酰胺类化合物的用途
US11357774B2 (en) 2019-03-06 2022-06-14 Hoyun Lee Use of a quinoline sulfonyl compound for treatment of inflammation, inflammatory disorders, autoimmune disorders and malaria
CN111671902B (zh) * 2020-03-19 2022-08-16 中山大学孙逸仙纪念医院 一种增敏剂药物及药物组合及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070244A1 (en) 2002-02-22 2003-08-28 Abbott Laboratories Antagonist of melanin concentrating hormone and their uses
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
WO2004002960A1 (en) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
WO2005066172A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
US20060035884A1 (en) * 2004-05-20 2006-02-16 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
WO2008049919A2 (en) * 2006-10-26 2008-05-02 Devgen N.V. Rho kinase inhibitors
WO2009148659A2 (en) * 2008-03-05 2009-12-10 Georgetown University Antimalarial quinolines and methods of use thereof
EP2296472A4 (en) * 2008-05-12 2011-06-08 Amnestix Inc COMPOUNDS FOR RHO KINASE INHIBITION AND FOR LEARNING AND REMINDERING IMPROVEMENT
WO2012041872A1 (en) 2010-09-29 2012-04-05 Intervet International B.V. N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases
WO2012079164A1 (en) 2010-12-16 2012-06-21 The Governing Council Of The University Of Toronto Activators of cylindrical proteases
US8785459B2 (en) * 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
DK2890981T3 (en) * 2012-08-28 2019-03-04 Univ Tuebingen Medizinische Fakultaet Senescence tracers
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato

Also Published As

Publication number Publication date
CN105308031B (zh) 2017-10-13
CA2903082C (en) 2021-06-22
CA2903082A1 (en) 2014-09-12
JP6509747B2 (ja) 2019-05-08
JP2016510732A (ja) 2016-04-11
WO2014134705A1 (en) 2014-09-12
EP2964625A1 (en) 2016-01-13
EP2964625B1 (en) 2018-07-25
US9975852B2 (en) 2018-05-22
US20150376132A1 (en) 2015-12-31
KR20150123908A (ko) 2015-11-04
CN105308031A (zh) 2016-02-03
EP2964625A4 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
BR112015021524A2 (pt) derivados de sulfonil quinolina e usos dos mesmos
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112015032693A2 (pt) inibidores de bromodomínio
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
CR20160099A (es) Formulación de inhibidores de la syk
DK2970216T3 (da) Biarylamidforbindelser som kinaseinhibitorer
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112015011830A2 (pt) compostos e seus métodos de utilização
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
BR112015023760A2 (pt) compostos e composições terapêuticas
NI201500096A (es) Compuesto químicos
BR112014022214A2 (pt) fenólicos antibacterianos
TR201909447T4 (tr) Aramkol tuzları.
BR112015029495A2 (pt) compostos heterocíclicos como inibidores da via de sinalização hedgehog
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201500931A1 (ru) Производные пиридин-4-ила
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]